Form 4: Abeona Therapeutics CEO Sells Shares for Tax Obligations

Abeona Therapeutics CEO Vishwas Seshadri reported the sale of 69,832 common shares on January 22, 2026, to cover tax liabilities from restricted stock vesting.

Summary

• Vishwas Seshadri, Chief Executive Officer and Director of Abeona Therapeutics Inc. (ABEO), reported a transaction on January 22, 2026.
• The transaction involved the disposition of 69,832 shares of Abeona Therapeutics common stock.
• The shares were sold at a weighted average price of $5.3309 per share, with individual transaction prices ranging from $5.33 to $5.38.
• The sale was conducted to cover tax obligations associated with the vesting of restricted stock awards.
• Following this transaction, Mr. Seshadri directly beneficially owns 1,460,408 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (sale to cover tax obligations from RSU vesting), which is a neutral event and does not reflect positively or negatively on the company's operational performance or future prospects.

Future Outlook

NA

Management Comments

• The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
• The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, common across all industries when executives receive and vest equity compensation. It does not provide specific industry-related insights or competitive analysis.

Stakeholder Impact

• Shareholders: May observe a slight increase in trading volume for ABEO shares due to the transaction. The sale, being for tax purposes, is generally not interpreted as a lack of confidence in the company by the insider.

Key Dates

Keywords

Abeona Therapeutics, ABEO, Vishwas Seshadri, Insider Trading, Form 4, Stock Sale, Tax Obligations, Restricted Stock Units, CEO